Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure

Abstract

Disclosed are the use of neuregulin proteins in preparing a medicine for preventing, treating or delaying preserved ejection fraction cardiac failure in mammals, and a method for using the medicine. Also provided in the present invention is a method for preventing, treating or delaying preserved ejection fraction cardiac failure in mammals, comprising using the medication containing the neuregulin proteins in a special population having the disease or being at risk of having the disease.

1 - 4 . (canceled) 
     
     
         5 . A pharmaceutical preparation for preventing, treating or delaying heart failure with preserved ejection fraction in a mammal, which comprises an effective amount of NRG. 
     
     
         6 . The pharmaceutical preparation of  claim 5 , wherein the neuregulin is NRG-I. 
     
     
         7 . The pharmaceutical preparation of  claim 5 , wherein the neuregulin comprises the amino acid sequence of SEQ ID NO: 1. 
     
     
         8 . The pharmaceutical preparation of  claim 5 , wherein the mammal is human. 
     
     
         9 . A composition for preventing, treating or delaying heart failure with preserved ejection fraction in a mammal, which comprises the pharmaceutical preparation of  claim 5  and other drug(s) for treating heart failure with preserved ejection fraction. 
     
     
         10 . A kit used for preventing, treating or delaying heart failure with preserved ejection fraction in a mammal, which comprises the pharmaceutical preparation of  claim 5  and instructions on how to use the pharmaceutical preparation.